AzTrials
AzTrials

Ankylosing Spondylitis (AS)Phase 2SELECT-AXIS 1NCT03178487

A Study Evaluating the Safety and Efficacy of Upadacitinib in Adults With Active Ankylosing Spondylitis

A Phase 2 study testing Upadacitinib in people with Ankylosing Spondylitis (AS), run by AbbVie at 101 sites in 21 countries.

Completed

Finished. The study has ended and is not enrolling. Results may be posted on the official record.

Official record
Search all trials

Trial summary

The purpose of this study is to evaluate the safety and efficacy of upadacitinib in participants with active ankylosing spondylitis (AS) who have had an inadequate response to at least 2 non-steroidal anti-inflammatory drugs (NSAIDs) or intolerance to or a contraindication for NSAIDs, and who are naïve to biologic… Read more about this study

Who is it for?
Ages 18 years and older
Conditions the study is for
Ankylosing Spondylitis (AS)
What is being tested?
Upadacitinib
Type of treatment
Pill or oral medicine
Could I receive a placebo?
Yes, some participants may receive a placebo
How many people
187 participants
Where
101 sitesin 21 countries
Study dates
24 Oct 2017to 17 Feb 2022
Phase
Phase 2
Are there results?
Yes, posted in the registrySummary in the doctors' view

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages 18 years and older
  • All sexes
  • No healthy volunteers
  • Adult, Older adult

Who may be able to join

  • Participant with a clinical diagnosis of ankylosing spondylitis (AS) and meeting the modified New York criteria for AS.
  • Participant must have baseline disease activity as defined by having a Bath Ankylosing Spondylitis Disease Activity Index (BASDAI) score >= 4 and a Patient's Assessment of Total Back Pain score >= 4 based on a 0 - 10 numeric rating scale (NRS) at the Screening and Baseline visits.
  • Participant has had an inadequate response to at least two nonsteroidal anti-inflammatory drugs (NSAIDs) over an at least 4-week period in total at maximum recommended or tolerated doses, or participant has an intolerance to or contraindication for NSAIDs as defined by the Investigator.
  • If entering the study on concomitant methotrexate (MTX), leflunomide, sulfasalazine (SSZ), and/or hydroxychloroquine, participant must be on a stable dose of MTX (<= 25 mg/week) and/or SSZ (<= 3 g/day) and/or hydroxychloroquine (<= 400 mg/day) or leflunomide (<= 20 mg/day) for at least 28 days prior to the Baseline visit. A combination of up to two background conventional synthetic disease-modifying anti-rheumatic drugs (csDMARDs) is allowed except the combination of MTX and leflunomide.
  • If entering the study on concomitant oral corticosteroids, participant must be on a stable dose of prednisone (<= 10 mg/day), or oral corticosteroid equivalents, for at least 14 days prior to the Baseline visit.
  • If entering the study on concomitant NSAIDs, tramadol, combination of acetaminophen and codeine or hydrocodone, and/or non-opioid analgesics, participant must be on stable dose(s) for at least 14 days prior to the Baseline visit.

Who cannot join

  • Prior exposure to any Janus kinase (JAK) inhibitor (including but not limited to tofacitinib, baricitinib, and filgotinib).
  • Prior exposure to any biologic therapy with a potential therapeutic impact on spondyloarthritis (SpA).
  • Intra-articular joint injections, spinal/paraspinal injection(s), or parenteral administration of corticosteroids within 28 days prior to the Baseline visit. Inhaled or topical corticosteroids are allowed.
  • Participant on any other DMARDs (other than those allowed), thalidomide or apremilast within 28 days or five half-lives (whichever is longer) of the drug prior to the Baseline visit.
  • Participant on opioid analgesics (except for combination acetaminophen/codeine or acetaminophen/hydrocodone which are allowed) or use of inhaled marijuana within 14 days prior to the Baseline visit.
  • Participant has a history of inflammatory arthritis of different etiology other than axial SpA (including but not limited to rheumatoid arthritis, psoriatic arthritis, mixed connective tissue disease, systemic lupus erythematosus, reactive arthritis, scleroderma, polymyositis, dermatomyositis, fibromyalgia), or any arthritis with onset prior to 17 years of age.
  • Laboratory values meeting the following criteria within the Screening period prior to the first dose of study drug: serum aspartate transaminase > 2 × upper limit of normal (ULN); serum alanine transaminase > 2 × ULN; estimated glomerular filtration rate by simplified 4-variable Modification of Diet in Renal Disease formula < 40 milliliter (mL)/minute/1.73m^2; hemoglobin < 10 gram/deciliter, total white blood cell count < 2,500/microliter (μL); absolute neutrophil count < 1,500/μL; absolute lymphocyte count < 800/μL; and platelet count < 100,000/μL.

Trial locations and contacts

101 sites in 21 countries.

101 sites in 21 countries

United States22 sites
  • Diagnostic Group Integrated He /ID# 165195

    Beaumont, Texas, 77701

  • David S. Hallegua MD /ID# 165090

    Beverly Hills, California, 90211

  • Bay Area Arthritis and Osteo /ID# 165023

    Brandon, Florida, 33511

  • DJL Clinical Research, PLLC /ID# 165044

    Charlotte, North Carolina, 28210-8508

  • Arth and Osteo Clin Brazo Valley /ID# 165194

    College Station, Texas, 77845

  • Covina Arthritis Clinic /ID# 165061

    Covina, California, 91722

  • Henry Ford Health System /ID# 165515

    Detroit, Michigan, 48202

  • Altoona Ctr Clinical Res /ID# 164470

    Duncansville, Pennsylvania, 16635

  • St. Joseph Health System /ID# 166166

    Fullerton, California, 92835

  • Aa Mrc Llc /Id# 165100

    Grand Blanc, Michigan, 48439

  • Comprehensive Arthritis Care, a division of Comprehensive Rheumatology Care PLLC /ID# 168107

    Hendersonville, Tennessee, 37075-6213

  • Colorado Arthritis Associates /ID# 164444

    Lakewood, Colorado, 80228

  • Global Research Foundation /ID# 165130

    Los Angeles, California, 90041

  • St. Lukes Clinic /ID# 165827

    Meridian, Idaho, 83642

  • LeJenue Research Associates /ID# 165202

    Miami, Florida, 33126

  • HMD Research LLC /ID# 205172

    Orlando, Florida, 32819

  • Arizona Arthritis & Rheumatolo /ID# 164446

    Phoenix, Arizona, 85032-9306

  • AZ Arthritis and Rheumotology Research, PLLC /ID# 165705

    Phoenix, Arizona, 85032-9306

  • St. Lawrence Health System /ID# 165025

    Potsdam, New York, 13676

  • Rheumatology Center of San Diego /ID# 166167

    San Diego, California, 92128-2549

  • Clinical Investigation Specialists - Skokie /ID# 164385

    Skokie, Illinois, 60076

  • Clinical Research Ctr Reading /ID# 164876

    Wyomissing, Pennsylvania, 19610

Other trials in United States

Japan17 sites
  • National Hospital Organization Asahikawa Medical Center /ID# 164566

    Asahikawa-shi, Hokkaido, 070-8644

  • Juntendo University Hospital /ID# 164738

    Bunkyo-ku, Tokyo, 113-8431

  • St.Luke's International Hospital /ID# 165219

    Chuo-ku, Tokyo, 104-8560

  • Saitama Medical University Hospital /ID# 164577

    Iruma-gun, Saitama, 350-0451

  • National Hospital Organization Osaka Minami Medical Center /ID# 164365

    Kawachinagano-shi, Osaka, 586-8521

  • Kagawa University Hospital /ID# 167517

    Kita-gun, Kagawa-ken, 761-0793

  • Hospital of the University of Occupational and Environmental Health /ID# 164380

    Kitakyushu-shi, Fukuoka, 807-8556

  • Juntendo University Koshigaya Hospital /ID# 165809

    Koshigaya-shi, Saitama, 343-0032

  • Gunma University Hospital /ID# 165683

    Maebashi, Gunma, 371-8511

  • Shinshu University Hospital /ID# 165304

    Matsumoto-shi, Nagano, 390-8621

  • Daido Hospital /ID# 163886

    Nagoya, 457-8511

  • Kochi Medical School Hospital /ID# 164460

    Nankoku-shi, Kochi, 783-8505

  • Japanese Red Cross Okayama Hospital /ID# 164376

    Okayama, Okayama-ken, 7008607

  • Okayama Saiseikai Outpatient Center Hospital /ID# 165595

    Okayama, 700-0013

  • Osaka City University Hospital /ID# 165253

    Osaka, Osaka, 545-8586

  • Osaka University Hospital /ID# 166033

    Suita-shi, Osaka, 565-0871

  • Tokushima University Hospital /ID# 165108

    Tokushima, Tokushima, 770-8503

Other trials in Japan

South Korea7 sites
  • Chonnam National University Hospital /ID# 164541

    Gwangju, Jeonranamdo, 61469

  • Gachon University Gil Medical Center /ID# 165114

    Incheon, Incheon Gwang Yeogsi, 21565

  • Chungnam National University Hospital /ID# 164561

    Junggu, Daejeon Gwang Yeogsi, 35015

  • Hanyang University Seoul Hospi /ID# 165811

    Seongdong-gu, Seoul Teugbyeolsi, 04763

  • Cath Univ Seoul St Mary's Hosp /ID# 164549

    Seoul, Seoul Teugbyeolsi, 06591

  • Kyunghee University Hospital at Gangdong /ID# 164569

    Seoul, 02447

  • Asan Medical Center /ID# 164557

    Seoul, 05505

Other trials in South Korea

Portugal5 sites
  • Instituto Portugues De Reumatologia /ID# 168314

    Lisbon, Lisbon District, 1050-034

  • Centro Hospitalar Lisboa Ocidental, EPE /ID# 168312

    Lisbon, Lisbon District, 1349-019

  • Hospital CUF Descobertas /ID# 168311

    Lisbon, 1998-018

  • Unidade Local De Saude Do Alto Minho /ID# 168310

    Viana do Castelo, 4901-858

  • Centro Hospitalar de Vila Nova Gaia/Espinho, EPE /ID# 168313

    Vila Nova de Gaia, Porto District, 4434-502

Other trials in Portugal

United Kingdom5 sites
  • Royal National Hosp for Rheuma /ID# 165147

    Bath, BA1 1RL

  • Glasgow Royal Infirmary /ID# 165152

    Glasgow, G4 0SF

  • Whipps Cross Univ Hospital /ID# 165150

    London, London, City of, E11 1NR

  • Norfolk and Norwich Univ Hosp /ID# 165149

    Norwich, Norfolk, NR4 7UY

  • Warrington and Halton Hospitals NHS Foundation Trust /ID# 166202

    Warrington, Cheshire West And Chester, WA5 1QG

Other trials in United Kingdom

Canada4 sites
  • Rheumatology Research Assoc /ID# 165240

    Edmonton, Alberta, T5M 0H4

  • University of Alberta - Division of Rheumatology /ID# 165239

    Edmonton, Alberta, T6G 2B7

  • Credit Valley Rheumatology /ID# 200087

    Mississauga, Ontario, L5M 2V8

  • Groupe de Recherche en Maladies Osseuses Inc /ID# 165238

    Sainte-Foy, Quebec, G1V 3M7

Other trials in Canada

Czechia4 sites
  • REVMACLINIC s.r.o. /ID# 167171

    Brno, 611 41

  • ARTHROHELP, s.r.o. /ID# 167001

    Pardubice, 530 02

  • Revmatologicky ustav Praha /ID# 167004

    Prague, Praha 2, 128 00

  • Thomayerova nemocnice /ID# 167003

    Prague, Praha 4, 140 00

Other trials in Czechia

Germany4 sites
  • Kerckhoff Klinik GmbH /ID# 165158

    Bad Nauheim, 61231

  • Charite - Campus Benjamin Franklin Medizinische Klinik - Rheumatologie /ID# 165153

    Berlin, 12203

  • Hamburger Rheuma Forschungszentrum II im MVZ Rheumatologie und Autoimmunmedizin /ID# 165146

    Hamburg, 20095

  • Rheumazentrum Ruhrgebiet /ID# 165148

    Herne, North Rhine-Westphalia, 44649

Other trials in Germany

Hungary4 sites
  • Revita Reumatologiai Rendelo /ID# 164724

    Budapest, 1027

  • University of Debrecen /ID# 165674

    Debrecen, 4032

  • Vita Verum Medical Bt. /ID# 165066

    Székesfehérvár, 8000

  • Vital Medical Center Orvosi-es Fogaszati Kozpont /ID# 164741

    Veszprém, 8200

Other trials in Hungary

Italy4 sites
  • Ospedale Sant Orsola Malpighi /ID# 165692

    Bologna, Emilia-Romagna, 40138

  • ASST G. Pini /ID# 165715

    Milan, 20122

  • Policlinico Paolo Giaccone /Id# 165663

    Palermo, Sicily, 90127

  • A.O. Universitaria Senese /ID# 165716

    Siena, 53100

Other trials in Italy

Belgium3 sites
  • ReumaClinic Genk /ID# 166018

    Genk, 3600

  • UZ Gent /ID# 166017

    Ghent, Oost-Vlaanderen, 9000

  • UZ Leuven /ID# 166019

    Leuven, 3000

Other trials in Belgium

France3 sites
  • CHU Bordeaux-Hopital Pellegrin /ID# 166309

    Bordeaux, 33076

  • CHRU Tours - Hopital Trousseau /ID# 165109

    Chambray-lès-Tours, 37170

  • CHRU de Montpellier - Hôpital Lapeyronie /ID# 166308

    Montpellier, 34090

Other trials in France

Poland3 sites
  • Osteo-Medic S.C. /ID# 165646

    Bialystok, Podlaskie Voivodeship, 15-351

  • ETYKA-Osrodek Badan Klinicznyc /ID# 165634

    Olsztyn, Warmian-Masurian Voivodeship, 10-117

  • NZOZ Nasz Lekarz /ID# 166023

    Torun, 87-100

Other trials in Poland

Spain3 sites
  • Hospital Parc de Salut del Mar /ID# 165027

    Barcelona, 08003

  • Corporac Sanitaria Parc Tauli /ID# 165029

    Barcelona, 08006

  • Hospital Unversitario Marques de Valdecilla /ID# 165028

    Santander, Cantabria, 39008

Other trials in Spain

Australia2 sites
  • Emeritus Research /ID# 169240

    Camberwell, Victoria, 3124

  • Princess Alexandra Hospital /ID# 169239

    Woolloongabba, Queensland, 4102

Other trials in Australia

Croatia2 sites
  • Clinical Hospital Dubrava /ID# 167049

    Zagreb, 10000

  • Medical Center Kuna-Peric /ID# 164851

    Zagreb, 10000

Other trials in Croatia

Finland2 sites
  • Helsinki Univ Central Hospital /ID# 165794

    Helsinki, 00290

  • Kiljava Medical Research /ID# 165793

    Hyvinkää, 05800

Other trials in Finland

Netherlands2 sites
  • Universitair Medisch Centrum Groningen /ID# 165681

    Groningen, 9713 GZ

  • Medisch Centrum Leeuwarden /ID# 166937

    Leeuwarden, 8934 AD

Other trials in Netherlands

New Zealand2 sites
  • Middlemore Hospital /ID# 169241

    Auckland, 2025

  • Waikato Hospital /ID# 169242

    Hamilton, Waikato Region, 3204

Other trials in New Zealand

Sweden2 sites
  • Skanes Universitetssjukhus /ID# 165712

    Malmö, Skåne County, 214 28

  • Reumatologkliniken /ID# 165713

    Västerås, 721 89

Other trials in Sweden

Denmark1 site
  • Vejle Sygehus /ID# 165190

    Vejle, Region Syddanmark, 7100

Other trials in Denmark

About this study

Official title: A Multicenter, Randomized, Double-Blind, Placebo-Controlled Study Evaluating the Safety and Efficacy of Upadacitinib in Subjects With Active Ankylosing Spondylitis

The purpose of this study is to evaluate the safety and efficacy of upadacitinib in participants with active ankylosing spondylitis (AS) who have had an inadequate response to at least 2 non-steroidal anti-inflammatory drugs (NSAIDs) or intolerance to or a contraindication for NSAIDs, and who are naïve to biologic disease-modifying anti-rheumatic drugs (bDMARD).

Read the detailed description

This study includes two periods: a 14-week double-blind placebo-controlled period and a 90-week open-label long-term extension period.

Eligible participants were randomly assigned in a 1:1 ratio to receive upadacitinib 15 mg or placebo for 14 weeks in Period 1.

Participants who completed Period 1 received upadacitinib 15 mg for 90 weeks in the extension period.

Being tested
Upadacitinib, Placebo
Keywords
Upadacitinib, ABT-494, Ankylosing Spondylitis (AS), Safety, Efficacy
Medical subject headings
Spondylitis, Ankylosing

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

  • UpadacitinibDrug

    Also called ABT-494, RINVOQ™

    Tablet

  • PlaceboDrug

    Tablet

Study groups in NCT03178487
Study groupRoleWhat they receive
Upadacitinib 15 mgExperimentalParticipants will receive 15 mg upadacitinib orally once a day for 14 weeks in Period 1 and continue to receive 15 mg upadacitinib orally once a day for an additional 90 weeks in Period 2.
Receives: Drug: Upadacitinib
PlaceboPlacebo comparatorParticipants will receive matching placebo orally once a day for 14 weeks in Period 1. In Period 2 participants will receive 15 mg upadacitinib orally once a day for 90 weeks.
Receives: Drug: Upadacitinib; Drug: Placebo

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. Percentage of Participants With Assessment of SpondyloArthritis International Society (ASAS) 40 Response at Week 14

    ASAS 40 response was defined as improvement of ≥ 40% relative to Baseline and absolute improvement of ≥ 2 units (on a scale from 0 to 10) in ≥ 3 of the following 4 domains with no deterioration (defined as a net worsening of > 0 units) in the potential remaining domain:

    • Patient's global assessment of disease activity, measured on a numeric rating scale (NRS) from 0 (no activity) to 10 (severe activity);
    • Pain, measured by the total back pain NRS from 0 (no pain) to 10 (most severe pain);
    • Function, measured by the Bath Ankylosing Spondylitis Functional Index (BASFI) which consists of 10 items assessing participants' ability to perform activities on an NRS ranging from 0 (easy) to 10 (impossible);
    • Inflammation, measured by the mean of the 2 morning stiffness-related Bath AS Disease Activity Index (BASDAI) NRS scores (items 5 [level of stiffness] and 6 [duration of stiffness]) each on a scale from 0 (none/0 hours) to 10 (very severe/2 hours or more duration).

    Measured: Baseline and Week 14

Secondary outcomes (12)
  1. Change From Baseline in Ankylosing Spondylitis Disease Activity Score (ASDAS) at Week 14

    ASDAS is a composite index to assess disease activity in Ankylosing Spondylitis. ASDAS combines the following 5 disease activity variables using a weighted formula:

    1. Patient's assessment of total back pain (BASDAI Question 2; NRS score 0 [none] - 10 [very severe])
    2. Patient global assessment of disease activity (NRS score 0 [no activity] - 10 [severe activity])
    3. Peripheral pain/swelling (BASDAI Question 3; NRS score 0 [none] - 10 [very severe])
    4. Duration of morning stiffness (BASDAI Question 6; NRS score 0 [0 hours] - 10 [2 or more hours])
    5. High-sensitivity C-reactive protein (hs-CRP) in mg/L.

    The overall score ranges from 0 with no defined upper score; published ranges for disease activity states as defined by the ASDAS include Inactive disease (ASDAS < 1.3) and very high disease (ASDAS > 3.5). A negative change from Baseline score indicates improvement in disease activity.

    Measured: Baseline and Week 14

  2. Change From Baseline in Spondyloarthritis Research Consortium of Canada (SPARCC) Magnetic Resonance Imaging (MRI) Score for the Spine at Week 14

    In the SPARCC MRI assessment of the spine, the entire spine is evaluated for active inflammation (bone marrow edema). Six discovertebral units (DVU) representing the 6 most abnormal DVUs were selected to calculate the MRI Spine SPARCC score. For each of the 6 DVUs, 3 consecutive sagittal slices were assessed in 4 quadrants to evaluate the extent of inflammation in all three dimensions.

    Each quadrant was scored for the presence (1) or absence (0) of edema. If edema was present in at least one quadrant of a DVU slice, it was also scored for intensity and depth of the edema representing that slice: An additional score of 1 was assigned if an intense signal was seen in any quadrant on a DVU slice. Slices that included a lesion demonstrating continuous increased signal of depth ≥ 1 cm extending from the endplate were scored as an additional 1 per slice.

    The maximum (worst) overall score for all 6 DVUs is 108.

    Measured: Baseline and Week 14

  3. Percentage of Participants With Bath Ankylosing Spondylitis Disease Activity Index (BASDAI) 50 Response at Week 14

    The BASDAI assesses disease activity by asking the participant to answer 6 questions (each on an 11 point numeric rating scale [NRS]) pertaining to symptoms experienced for the past week. For Questions 1 to 5 (level of fatigue/tiredness, level of AS neck, back or hip pain, level of pain/swelling in joints, other than neck, back or hips, level of discomfort from any areas tender to touch or pressure, and level of morning stiffness), the response is from 0 (none) to 10 (very severe); for Question 6 (duration of morning stiffness), the response is from 0 (0 hours) to 10 (≥ 2 hours). The overall BASDAI score ranges from 0 to 10. Lower scores indicate less disease activity.

    A BASDAI 50 response is defined as improvement of 50% or more from Baseline in BASDAI score.

    Measured: Baseline and Week 14

  4. Change From Baseline in Ankylosing Spondylitis Quality of Life (ASQoL) Score

    The ASQoL consists of 18 items related to quality of life, including the impact of pain on sleep, mood, motivation, ability to cope, activities of daily living, independence, relationships, and social life. Each item is answered as yes (scored as 1) or no (scored as 0).

    Scores are summed to obtain the overall score which ranges from 0 to 18, where higher scores indicate a worse quality of life. A negative change from Baseline in ASQoL indicates improvement in quality of life.

    Measured: Baseline and Week 14

  5. Percentage of Participants Achieving an Assessment of Spondyloarthritis International Society (ASAS) Partial Remission

    ASAS partial remission (PR) is defined as an absolute score of ≤ 2 units on a 0 to 10 scale for each of the four following domains:

    • Patient's global assessment of disease activity, measured on a numeric rating scale (NRS) from 0 (no activity) to 10 (severe activity);
    • Pain, measured by the total back pain NRS from 0 (no pain) to 10 (most severe pain);
    • Function, measured by the Bath Ankylosing Spondylitis Functional Index (BASFI) which consists of 10 items assessing participants' ability to perform activities on an NRS ranging from 0 (easy) to 10 (impossible);
    • Inflammation, measured by the mean of the 2 morning stiffness-related Bath AS Disease Activity Index (BASDAI) NRS scores (items 5 [level of stiffness] and 6 [duration of stiffness]) each on a scale from 0 (none/0 hours) to 10 (very severe/2 hours or more duration).

    Measured: Week 14

  6. Change From Baseline in Bath Ankylosing Spondylitis Functional Index (BASFI) at Week 14

    The Bath Ankylosing Spondylitis Functional Index is a validated index to determine the degree of functional limitation in patients with AS. BASFI consists of 10 questions assessing participants' ability to perform activities such as putting on socks, bending, reaching, getting up from the floor or an armless chair, standing, climbing and other physical activities. Each item is scored on a NRS ranging from 0 (easy to perform an activity) to 10 (impossible to perform an activity). The overall score is the mean of the 10 items and ranges from 0 to 10 with higher scores indicating more functional limitations. A negative change from Baseline in BASFI indicates improvement.

    Measured: Baseline and Week 14

  7. Change From Baseline in Linear Bath Ankylosing Spondylitis Metrology Index (BASMI[Lin]) at Week 14

    The BASMI is a composite score based on 5 direct measurements of spinal mobility:

    1. cervical rotation (measured in degrees),
    2. tragus to wall distance (in centimeters [cm])
    3. lumbar side flexion (in cm),
    4. lumbar flexion (modified Schober's) (in cm) and
    5. intermalleolar distance (in cm).

    Each measurement is converted to a linear score between 0 and 10. The total BASMI score is the average of the 5 scores and ranges from 0 to 10; the higher the BASMI score the more severe the patient's limitation of movement due to their ankylosing spondylitis. A negative change from Baseline indicates improvement.

    Measured: Baseline and Week 14

  8. Change From Baseline in Maastricht Ankylosing Spondylitis Enthesitis Score (MASES) at Week 14

    The MASES evaluation was conducted to assess the presence or absence of enthesitis (inflammation of the entheses, or sites where tendons or ligaments insert into the bone) at 13 different sites (first costochondral joint left/right, seventh costochondral joint left/right, posterior superior iliac spine left/right, anterior superior iliac spine left/right, iliac crest left/right, fifth lumbar spinous process, and proximal insertion of Achilles tendon left/right. Each site was scored for presence (1) or absence (0) of enthesitis. The MASES is the sum of the 13 site scores, and ranges from 0 to 13, with higher scores indicating more inflammation of the entheses.

    Measured: Baseline and Week 14

  9. Change From Baseline in Work Productivity and Activity Impairment (WPAI) Overall Work Impairment at Week 14

    The Work Productivity and Activity Impairment Questionnaire: Axial Spondyloarthritis, Version 2.0 (WPAI-Axial Spondyloarthritis) measures the effect of overall health and specific symptoms on productivity at work and outside of work. It consists of 6 questions. Respondents were asked about time missed from work and time while at work during which productivity was impaired in the past seven days. Results of WPAI are expressed as a percentage of impairment from 0 to 100, with higher percentages indicating greater impairment and less productivity. Overall Work Impairment indicates the percentage of overall work impairment due to health problems. A negative change from Baseline indicates improvement.

    Measured: Baseline and Week 14

  10. Change From Baseline in ASAS Health Index (HI) at Week 14

    The ASAS HI measures functioning and health across 17 aspects of health in patients with AS, including pain, emotional functions, sleep, sexual function, mobility, self care, and community life. Each of the 17 questions is answered by the participant as "I agree" (score = 1) or "I disagree" (score = 0). The responses to the 17 dichotomous items are summed up to give a total score ranging from 0 to 17, where a higher score indicates a worse health status. A negative change from Baseline indicates improvement.

    Measured: Baseline and Week 14

  11. Percentage of Participants Achieving an ASAS 20 Response at Week 14

    ASAS 20 response was defined as an improvement of ≥ 20% and an absolute improvement of ≥ 1 unit (on a scale of 0 to 10) from Baseline in at least 3 of the following 4 domains, with no deterioration (defined as a worsening of ≥ 20% and a net worsening of ≥ 1 units [on a scale of 0 to 10]) in the remaining domain:

    • Patient's global assessment of disease activity, measured on a NRS from 0 (no activity) to 10 (severe activity);
    • Pain, measured by the total back pain NRS from 0 (no pain) to 10 (most severe pain);
    • Function, measured by the BASFI which consists of 10 items assessing participants' ability to perform activities on an NRS ranging from 0 (easy) to 10 (impossible);
    • Inflammation, measured by the mean of the 2 morning stiffness-related BASDAI NRS scores (items 5 [level of stiffness] and 6 [duration of stiffness]) each on a scale from 0 (none/0 hours) to 10 (very severe/2 hours or more duration).

    Measured: Baseline and Week 14

  12. Change From Baseline in SPARCC MRI Score for Sacroiliac Joints at Week 14

    In the SPARCC MRI assessment of the sacroiliac (SI) joints 6 consecutive sacroiliac joint image coronal slices representing the largest proportion of the synovial compartment of the SI joints were assessed for edema, intensity and depth of edema.

    Each SI joint (left and right) was divided into quadrants for a total of 8 SI scoring locations. Each quadrant was scored for the presence (1) or absence (0) of edema, intensity of edema (a score of 1 was assigned for each SI joint (left and right) if an intense signal was seen in any quadrant of that joint for each slice), and a lesion was graded as deep (score of 1) if there was homogeneous and unequivocal increase in signal extending over a depth of at least 1 cm from the articular surface of the SI joint in any quadrant.

    The total maximum score for all SI joints across 6 slices is 72.

    Measured: Baseline and Week 14

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted7 Jun 2017
  2. Study start24 Oct 2017
  3. Primary completion21 Jan 2019
  4. Study completion17 Feb 2022

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Interventional
Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomised
Intervention model
Parallel groups
Masking
Quadruple blind
Who is masked
Participant, Care provider, Investigator, Outcomes assessor
Enrolment
187 participants (actual)
IDs, dates and publications
ClinicalTrials.gov ID
NCT03178487
Sponsor's protocol ID
M16-098
Other IDs
2017-000431-14, 2017
Acronym
SELECT-AXIS 1
Status last verified
Feb 2023
First submitted
5 Jun 2017
Last updated
7 Mar 2023
Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
Individual data sharing
Yes: AbbVie is committed to responsible data sharing regarding the clinical trials we sponsor. This includes access to anonymized, individual and trial-level data (analysis data sets), as well as other information (e.g., protocols, analyses plans, clinical study reports), as long as the trials are not part of an ongoing or planned regulatory submission. This includes requests for clinical trial data for unlicensed products and indications.

Publications

  • van der Heijde D, Song IH, Pangan AL, Deodhar A, van den Bosch F, Maksymowych WP, Kim TH, Kishimoto M, Everding A, Sui Y, Wang X, Chu AD, Sieper J. Efficacy and safety of upadacitinib in patients with active ankylosing spondylitis (SELECT-AXIS 1): a multicentre, randomised, double-blind, placebo-controlled, phase 2/3 trial. Lancet. 2019 Dec 7;394(10214):2108-2117. doi: 10.1016/S0140-6736(19)32534-6. Epub 2019 Nov 12.

    PubMed 31732180
  • Baraliakos X, Bessette L, de Vlam K, Taylor PC, Biljan A, Urbanik J, Gao T, Jasion VS, Kato K, Lippe R, Magrey M. Impact of Upadacitinib on Reducing Pain in Patients Across the Axial Spondyloarthritis Spectrum: A Post Hoc Analysis of the Phase 2/3 SELECT-AXIS Studies. Rheumatol Ther. 2026 Jun;13(3):611-628. doi: 10.1007/s40744-026-00834-5. Epub 2026 Mar 13.

    PubMed 41824252
  • Zhang X, Jia L, Lin X, Zhou L. Exhaustion-Resistant CD8 + T Cells in Ankylosing Spondylitis: A Proposed Three-Axis Model. Immunology. 2025 Dec;176(4):409-420. doi: 10.1111/imm.70044. Epub 2025 Oct 2.

    PubMed 41039829
  • Burmester GR, Deodhar A, Irvine AD, Panaccione R, Winthrop KL, Vleugels RA, Levy G, Suravaram S, Palac H, Wegrzyn L, Ford S, Meerwein S, Guttman-Yassky E. Safety Profile of Upadacitinib: Descriptive Analysis in Over 27,000 Patient-Years Across Rheumatoid Arthritis, Psoriatic Arthritis, Axial Spondyloarthritis, Atopic Dermatitis, and Inflammatory Bowel Disease. Adv Ther. 2025 Oct;42(10):5215-5237. doi: 10.1007/s12325-025-03328-y. Epub 2025 Aug 28.

    PubMed 40875187
  • Navarro-Compan V, Van den Bosch F, Sampaio-Barros PD, Ostor AJK, Parikh B, Kato K, Gao T, Stigler J, Ramiro S. Efficacy of upadacitinib in subgroups of patients with axial spondyloarthritis with early versus established disease. RMD Open. 2025 Mar 4;11(1):e005110. doi: 10.1136/rmdopen-2024-005110.

    PubMed 40037923
  • Poddubnyy D, Parikh B, Elewaut D, Navarro-Compan V, Siebert S, Paley M, Coombs D, Lagunes I, Biljan A, Nakasato P, Wung P, Lubrano E. Development of Extramusculoskeletal Manifestations in Upadacitinib-Treated Patients With Psoriatic Arthritis or Axial Spondyloarthritis. Arthritis Rheumatol. 2025 May;77(5):536-546. doi: 10.1002/art.43069. Epub 2025 Jan 24.

    PubMed 39624020
  • Burmester GR, Stigler J, Rubbert-Roth A, Tanaka Y, Azevedo VF, Coombs D, Lagunes I, Lippe R, Wung P, Gensler LS. Safety Profile of Upadacitinib up to 5 Years in Psoriatic Arthritis, Ankylosing Spondylitis, and Non-radiographic Axial Spondyloarthritis: An Integrated Analysis of Clinical Trials. Rheumatol Ther. 2024 Jun;11(3):737-753. doi: 10.1007/s40744-024-00671-4. Epub 2024 Apr 29.

    PubMed 38683479
  • Rubbert-Roth A, Kakehasi AM, Takeuchi T, Schmalzing M, Palac H, Coombs D, Liu J, Anyanwu SI, Lippe R, Curtis JR. Malignancy in the Upadacitinib Clinical Trials for Rheumatoid Arthritis, Psoriatic Arthritis, Ankylosing Spondylitis, and Non-radiographic Axial Spondyloarthritis. Rheumatol Ther. 2024 Feb;11(1):97-112. doi: 10.1007/s40744-023-00621-6. Epub 2023 Nov 20.

    PubMed 37982966
  • Charles-Schoeman C, Choy E, McInnes IB, Mysler E, Nash P, Yamaoka K, Lippe R, Khan N, Shmagel AK, Palac H, Suboticki J, Curtis JR. MACE and VTE across upadacitinib clinical trial programmes in rheumatoid arthritis, psoriatic arthritis and ankylosing spondylitis. RMD Open. 2023 Nov;9(4):e003392. doi: 10.1136/rmdopen-2023-003392.

    PubMed 37945286
  • Burmester GR, Cohen SB, Winthrop KL, Nash P, Irvine AD, Deodhar A, Mysler E, Tanaka Y, Liu J, Lacerda AP, Palac H, Shaw T, Mease PJ, Guttman-Yassky E. Safety profile of upadacitinib over 15 000 patient-years across rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis and atopic dermatitis. RMD Open. 2023 Feb;9(1):e002735. doi: 10.1136/rmdopen-2022-002735.

    PubMed 36754548
  • Deodhar A, van der Heijde D, Sieper J, Van den Bosch F, Maksymowych WP, Kim TH, Kishimoto M, Ostor A, Combe B, Sui Y, Chu AD, Song IH. Safety and Efficacy of Upadacitinib in Patients With Active Ankylosing Spondylitis and an Inadequate Response to Nonsteroidal Antiinflammatory Drug Therapy: One-Year Results of a Double-Blind, Placebo-Controlled Study and Open-Label Extension. Arthritis Rheumatol. 2022 Jan;74(1):70-80. doi: 10.1002/art.41911. Epub 2021 Nov 12.

    PubMed 34196498

Questions about this trial

What is this clinical trial studying?

A Phase 2 study testing Upadacitinib in people with Ankylosing Spondylitis (AS), run by AbbVie at 101 sites in 21 countries.

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

The sponsor lists 6 inclusion and 7 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: finished, as of the sponsor's last update on 7 Mar 2023. Status can change between updates, so confirm with the study contact before making plans.

Where is the study taking place?

The record lists 101 sites in United States, Japan, South Korea, Portugal, United Kingdom and 16 more countries. Whether a site is taking part right now should be confirmed with that site. See every site.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. Some participants in this study may receive a placebo. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

What does this phase mean?

Phase 2 studies give the treatment to a larger group to see whether it has the intended effect and to keep checking safety.

Not every study follows the same path, and some studies (observational studies, device studies) have no phase.

Are results available for this study?

Yes. Results are posted in the registry (first posted 1 Jun 2021). A summary is in the For doctors view, and the full results are on ClinicalTrials.gov.

How can a doctor refer a patient or contact the research team?

The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

Percentage of Participants With Assessment of SpondyloArthritis International Society (ASAS) 40 Response at Week 14 (time frame: Baseline and Week 14). It is what the study was designed to measure, not a finding.

Where can I read the original study information?

On the ClinicalTrials.gov record for NCT03178487, which also lists 11 linked publications.

Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 7 Mar 2023; AzTrials last refreshed its copy on 6 Nov 2026.

Free account

Log in to keep searching

You’ve used your 3 free searches. AzTrials is free: log in or create a free account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in